Ubs Group Ag Acorda Therapeutics Inc Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.55 - $1.0 $4,002 - $7,277	-7,277 Reduced 54.71%	6,025 $3,000
Q4 2022 Feb 08, 2023	BUY	$0.52 - $0.77 $646 - $957	1,243 Added 10.31%	13,302 $10,000
Q3 2022 Nov 10, 2022	SELL	$0.29 - $0.53 $4,825 - $8,818	-16,639 Reduced 57.98%	12,059 $4,000
Q2 2022 Aug 10, 2022	BUY	$0.3 - $1.67 $7,764 - $43,224	25,883 Added 919.47%	28,698 $13,000
Q1 2022 May 16, 2022	BUY	$1.61 - $2.5 $4,504 - $6,995	2,798 Added 16458.82%	2,815 $4,000
Q4 2021 Feb 14, 2022	SELL	$2.3 - $4.71 $10,278 - $21,048	-4,469 Reduced 99.62%	17 $0
Q3 2021 Nov 15, 2021	BUY	$3.36 - $4.79 $14,874 - $21,205	4,427 Added 7503.39%	4,486 $20,000
Q1 2021 May 12, 2021	BUY	$3.8 - $8.04 $224 - $474	59 New	59 $0

133K

Ticker ACOR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 24,338,400
Market Cap $6.33M
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.